Report of Foreign Issuer (6-k)
23 February 2018 - 8:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of February 2018
001-37353
(Commission
File Number)
BIONDVAX
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
14
Einstein St.
Ness
Ziona
Israel 7414002
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
____
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If
“Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-N/A
BiondVax Pharmaceuticals
Ltd. (hereinafter, the “Registrant”, the “Company”, or “BiondVax”) announces that it will
hold an Annual and Extraordinary General Meeting of Shareholders on March 28, 2018, at 4:00 p.m. Israel time, at the offices of
Pearl Cohen Zedek Latzer Baratz, the new Azrieli Sarona Tower, 121 Menachem Begin Road, 53rd. floor, Tel Aviv, Israel.
The
Company hereby furnishes the following documents:
|
i.
|
Notice
and Proxy Statement with respect to the Company’s
Annual
and Extraordinary General Meeting of Shareholders
to be held on March 28, 2018, describing
the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other
details related to the meeting; and
|
|
ii.
|
a
Proxy Card whereby holders of Company’s shares may vote at the meeting without attending in person.
|
The
Notice and Proxy Statement is furnished with this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K
as Exhibit 99.2.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: February 22, 2018
|
By:
|
/s/
Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2024 to May 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From May 2023 to May 2024